<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04053088</url>
  </required_header>
  <id_info>
    <org_study_id>IPPM2019IMPACT</org_study_id>
    <nct_id>NCT04053088</nct_id>
  </id_info>
  <brief_title>SAVR: IMPACT of Pre-existing Comorbidities on Patient Outcomes and Prosthetic Valve Performance in a Real-world Setting.</brief_title>
  <acronym>IMPACT</acronym>
  <official_title>Surgical Aortic Valve Replacement: IMPACT of Pre-existing Comorbidities on Patient Outcomes and Prosthetic Valve Performance in a Real-world Setting.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut für Pharmakologie und Präventive Medizin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Edwards Lifesciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut für Pharmakologie und Präventive Medizin</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The INSPIRIS Registry represents a non-interventional, prospective, open-label, multicenter,
      international registry with a follow-up of 5 years that includes data of patients undergoing
      aortic valve replacement with the Edwards INSPIRIS RESILIA Aortic Valve™. The INSPIRIS
      Registry will be performed in up to 25 participating sites across Germany, Austria and
      Switzerland. A minimum number of 500 patients (20 patients per center) will be enrolled.
      Patients will undergo follow-up visits at baseline, surgery, pre-discharge, year 1, year 3
      and year 5.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The INSPIRIS RESILIA Aortic Valve™ is a stented tri-leaflet valve comprised of bovine
      pericardial tissue. The tissue is created by treating bovine pericardial tissue with Edwards
      Integrity Preservation. It incorporates a stable capping anticalcification process, which
      blocks residual aldehyde groups known to bind with calcium. Tissue preservation with glycerol
      allows the valve to be stored without a traditional liquid-based solution, such as
      glutaraldehyde. Therefore, valve is stored under dry packaging conditions and consequently
      does not require rinsing prior to implantation.

      The novel tissue preservation technology significantly improves hemodynamic and
      anticalcification properties compared with the standard Perimount valve in an ovine model
      (Flameng et al., 2015). The RESILIA tissue has been studied in the COMMENCE trial: Two year
      data show that the NYHA class improved in 65.7% of patients, effective orifice area after
      implantation was 1.6 ± 0.5 cm2; mean gradient was 10.1 ± 4.3 mmHg; and paravalvular leak was
      none/trivial in 94.5% of patients (mild to moderate in 0.5%) (Puskas et al., 2017).

      On the sizes 19 - 25 mm the INSPIRIS RESILIA Aortic Valve™ has been outfitted with the VFit
      technology, which incorporates two novel features designed for potential future
      valve-in-valve procedures: fluoroscopically visible size markers and an expandable cobalt
      chromium alloy band. No clinical data are available that evaluate the use of the INSPIRIS
      RESILIA Aortic Valve™ in patients to date.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 12, 2019</start_date>
  <completion_date type="Anticipated">August 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>after 1 year</time_frame>
    <description>All-cause mortality after 1 year will be investigated</description>
  </primary_outcome>
  <primary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>after 3 years</time_frame>
    <description>All-cause mortality after 3 years will be investigated</description>
  </primary_outcome>
  <primary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>after 5 years</time_frame>
    <description>All-cause mortality after 5 years will be investigated</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>after 1 year</time_frame>
    <description>All cause, cardiac and valve-related mortality in the overall study population and in different patient subgroups at all timepoints: Chronic kidney disease, diabetes, hypertension, metabolic syndrome, inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>after 3 years</time_frame>
    <description>All cause, cardiac and valve-related mortality in the overall study population and in different patient subgroups at all timepoints: Chronic kidney disease, diabetes, hypertension, metabolic syndrome, inflammation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>after 5 years</time_frame>
    <description>All cause, cardiac and valve-related mortality in the overall study population and in different patient subgroups at all timepoints: Chronic kidney disease, diabetes, hypertension, metabolic syndrome, inflammation</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in Maximum pressure gradient (Pmax) over time</measure>
    <time_frame>after 1 year</time_frame>
    <description>Change in Pmax in mmHg as an indicator of patient prosthesis mismatch</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Maximum pressure gradient (Pmax) over time</measure>
    <time_frame>after 3 years</time_frame>
    <description>Change in Pmax in mmHg as an indicator of patient prosthesis mismatch</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in Maximum pressure gradient (Pmax) over time</measure>
    <time_frame>after 5 years</time_frame>
    <description>Change in Pmax in mmHg as an indicator of patient prosthesis mismatch</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in mean pressure gradient (Pmean) over time</measure>
    <time_frame>after 1 year</time_frame>
    <description>Change in Pmean in mmHg as an indicator of patient prosthesis mismatch</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in mean pressure gradient (Pmean) over time</measure>
    <time_frame>after 3 years</time_frame>
    <description>Change in Pmean in mmHg as an indicator of patient prosthesis mismatch</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in mean pressure gradient (Pmean) over time</measure>
    <time_frame>after 5 years</time_frame>
    <description>Change in Pmean in mmHg as an indicator of patient prosthesis mismatch</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in velocity time integral (VTI) over time</measure>
    <time_frame>after 1 year</time_frame>
    <description>Change in VTI as an indicator of patient prosthesis mismatch</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in velocity time integral (VTI) over time</measure>
    <time_frame>after 3 years</time_frame>
    <description>Change in VTI as an indicator of patient prosthesis mismatch</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in velocity time integral (VTI) over time</measure>
    <time_frame>after 5 years</time_frame>
    <description>Change in VTI as an indicator of patient prosthesis mismatch</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in prostesis opening area (EOA) over time</measure>
    <time_frame>after 1 year</time_frame>
    <description>Change in EOA in mm2 as an indicator of patient prosthesis mismatch</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in prostesis opening area (EOA) over time</measure>
    <time_frame>after 3 years</time_frame>
    <description>Change in EOA in mm2 as an indicator of patient prosthesis mismatch</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in prostesis opening area (EOA) over time</measure>
    <time_frame>after 5 years</time_frame>
    <description>Change in EOA in mm2 as an indicator of patient prosthesis mismatch</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in left ventricular ejection fraction (LVEF) over time</measure>
    <time_frame>after 1 year</time_frame>
    <description>Change in LVEF in % as an indicator of patient prosthesis mismatch</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in left ventricular ejection fraction (LVEF) over time</measure>
    <time_frame>after 3 years</time_frame>
    <description>Change in LVEF in % as an indicator of patient prosthesis mismatch</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in left ventricular ejection fraction (LVEF) over time</measure>
    <time_frame>after 5 years</time_frame>
    <description>Change in LVEF in % as an indicator of patient prosthesis mismatch</description>
  </other_outcome>
  <other_outcome>
    <measure>Occurence of paravalvular leaks</measure>
    <time_frame>after 1 year</time_frame>
    <description>Occurence of paravalvular leaks as an indicator of patient prostheis mismatch</description>
  </other_outcome>
  <other_outcome>
    <measure>Occurence of paravalvular leaks</measure>
    <time_frame>after 3 years</time_frame>
    <description>Occurence of paravalvular leaks as an indicator of patient prostheis mismatch</description>
  </other_outcome>
  <other_outcome>
    <measure>Occurence of paravalvular leaks</measure>
    <time_frame>after 5 years</time_frame>
    <description>Occurence of paravalvular leaks as an indicator of patient prostheis mismatch</description>
  </other_outcome>
  <other_outcome>
    <measure>Occurence of structural valve detioration (SVD) over time</measure>
    <time_frame>after 1 year</time_frame>
    <description>SVD to be determined by imaging methods (e.g. Echocardiography) following Salaun et al. 2018</description>
  </other_outcome>
  <other_outcome>
    <measure>Occurence of structural valve detioration (SVD) over time</measure>
    <time_frame>after 3 years</time_frame>
    <description>SVD to be determined by imaging methods (e.g. Echocardiography) following Salaun et al. 2018</description>
  </other_outcome>
  <other_outcome>
    <measure>Occurence of structural valve detioration (SVD) over time</measure>
    <time_frame>after 5 years</time_frame>
    <description>SVD to be determined by imaging methods (e.g. Echocardiography) following Salaun et al. 2018</description>
  </other_outcome>
  <other_outcome>
    <measure>Occurence of repeat procedures (valve-in-valve reoperation)</measure>
    <time_frame>after 1 year</time_frame>
    <description>Any repeat procedures will be documented and assessed</description>
  </other_outcome>
  <other_outcome>
    <measure>Occurence of repeat procedures (valve-in-valve reoperation)</measure>
    <time_frame>after 3 years</time_frame>
    <description>Any repeat procedures will be documented and assessed</description>
  </other_outcome>
  <other_outcome>
    <measure>Occurence of repeat procedures (valve-in-valve reoperation)</measure>
    <time_frame>after 5 years</time_frame>
    <description>Any repeat procedures will be documented and assessed</description>
  </other_outcome>
  <other_outcome>
    <measure>New York Heart Association (NYHA) functional class compared to baseline</measure>
    <time_frame>after 1 year</time_frame>
    <description>NYHA class will be determined at follow-up visits</description>
  </other_outcome>
  <other_outcome>
    <measure>New York Heart Association (NYHA) functional class compared to baseline</measure>
    <time_frame>after 3 years</time_frame>
    <description>NYHA class will be determined at follow-up visits</description>
  </other_outcome>
  <other_outcome>
    <measure>New York Heart Association (NYHA) functional class compared to baseline</measure>
    <time_frame>after 5 years</time_frame>
    <description>NYHA class will be determined at follow-up visits</description>
  </other_outcome>
  <other_outcome>
    <measure>Freedom from valve-related rehospitalization</measure>
    <time_frame>after 1 year</time_frame>
    <description>any valve related hospitalizations will be documented and assessed</description>
  </other_outcome>
  <other_outcome>
    <measure>Freedom from valve-related rehospitalization</measure>
    <time_frame>after 3 years</time_frame>
    <description>any valve related hospitalizations will be documented and assessed</description>
  </other_outcome>
  <other_outcome>
    <measure>Freedom from valve-related rehospitalization</measure>
    <time_frame>after 5 years</time_frame>
    <description>any valve related hospitalizations will be documented and assessed</description>
  </other_outcome>
  <other_outcome>
    <measure>Need for new pacemaker implant</measure>
    <time_frame>after 1 year</time_frame>
    <description>Any occurence of new pacemaker implant (e. g. when the participant did not have a pacemaker at baseline) will be documented and assessed</description>
  </other_outcome>
  <other_outcome>
    <measure>Need for new pacemaker implant</measure>
    <time_frame>after 3 years</time_frame>
    <description>Any occurence of new pacemaker implant (e. g. when the participant did not have a pacemaker at the preceding follow-up visit) will be documented and assessed</description>
  </other_outcome>
  <other_outcome>
    <measure>Need for new pacemaker implant</measure>
    <time_frame>after 5 years</time_frame>
    <description>Any occurence of new pacemaker implant (e. g. when the participant did not have a pacemaker at the preceding follow-up visit) will be documented and assessed</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>SAVR patients</arm_group_label>
    <description>patients undergoing surgical aortic valve replacement (SAVR) by usage of the INSPIRIS RESILIA Aortic valve™</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>INSPIRIS RESILIA Aortic Valve™</intervention_name>
    <description>Collection of patient data from patients undergoing Surgical Aortic Valve Replacement (SAVR) by usage of the INSPIRIS RESILIA aortic valve™</description>
    <arm_group_label>SAVR patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Minimum of 500 patients (20 patients per center) undergoing Surgical Aortic Valve
        Replacement (SAVR) using the INSPIRIS RESILIA aortic valve™ (all comers).

        The required sample size was calculated using the online calculator at
        http://www.surveysystem.com/sscalc.htm. It was estimated, from the COMMENCE Trial dataset
        (Puskas et al., 2017) that all-cause mortality is around 1.2% at year 1 and 2.0% at year 2.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient is at least 18 years old

          2. Patient has an aortic valve vitium and requires an aortic valve replacement with the
             Edwards INSPIRIS RESILIA Aortic Valve™

          3. Patient is scheduled to attend yearly follow-up visits at the registry center up to 5
             years

          4. Patient provides written informed consent prior to the procedure and in case of
             emergency after the procedure.

        Exclusion Criteria:

          1. Disability and / or other circumstances under which the patient is not capable to
             understand the nature, significance and scope of the clinical trial

          2. Active endocarditis/myocarditis or endocarditis/myocarditis within 3 months prior to
             the scheduled aortic valve replacement surgery

          3. Patient has a life expectancy ≤ 12 months for any reason

          4. Valve implantation is not possible in accordance with the device IFU

          5. Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Farhad Bakhtiary, Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helios Klinik Siegburg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andreas Zierer, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kepler University Hosiptal Linz and Hospital Wels-Grieskirchen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Beate Botta, PhD</last_name>
    <phone>+4944718503325</phone>
    <email>beate.botta@ippmed.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Claudia Lueske, PhD</last_name>
    <phone>+4944718503324</phone>
    <email>claudia.lueske@ippmed.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kepler Universitätsklinikum Linz</name>
      <address>
        <city>Linz</city>
        <zip>4021</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Zierer, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Bergmannsheil</name>
      <address>
        <city>Bochum</city>
        <zip>44789</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Justus Strauch, Prof.</last_name>
      <email>justus.strauch@bergmannsheil.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum Siegburg</name>
      <address>
        <city>Siegburg</city>
        <zip>53721</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Farhad Bakhtiary, Prof. Dr.</last_name>
      <email>farhad.bakhtiary@helios-gesundheit.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum Wuppertal</name>
      <address>
        <city>Wuppertal</city>
        <zip>42283</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Farhad Bakhtiary, Prof. Dr.</last_name>
      <email>farhad.bakhtiary@helios-gesundheit.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Salaun E, Clavel MA, Rodés-Cabau J, Pibarot P. Bioprosthetic aortic valve durability in the era of transcatheter aortic valve implantation. Heart. 2018 Aug;104(16):1323-1332. doi: 10.1136/heartjnl-2017-311582. Epub 2018 May 7. Review.</citation>
    <PMID>29735584</PMID>
  </reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>August 6, 2019</study_first_submitted>
  <study_first_submitted_qc>August 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2019</study_first_posted>
  <last_update_submitted>February 5, 2020</last_update_submitted>
  <last_update_submitted_qc>February 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Surgical Aortic Valve Replacement (SAVR)</keyword>
  <keyword>INSPIRIS RESILIA</keyword>
  <keyword>Durability</keyword>
  <keyword>Hemodynamics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

